<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142975">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01976884</url>
  </required_header>
  <id_info>
    <org_study_id>NeutrophilPD-L1</org_study_id>
    <nct_id>NCT01976884</nct_id>
  </id_info>
  <brief_title>Expression and the Clinical Significance of Neutrophil PD-L1 During Sepsis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <authority>China: National Natural Science Foundation</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunosuppression is the leading cause of death in septic patients. Neutrophils are
      classical components of innate immunology, but recent studies showed that neutrophils might
      display antigen presenting function and inhibit lymphocyte proliferation by expressing
      programmed cell death 1 ligand 1 (PD-L1). Whether neutrophils express PD-L1 and its role in
      immunosuppression during sepsis remain unclear.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>PD-L1 level on neutrophils</measure>
    <time_frame>within 24h after recruitment</time_frame>
    <safety_issue>No</safety_issue>
    <description>PD-L1 level on neutrophils was compared between different populations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days after diagnosis of sepsis</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">71</enrollment>
  <condition>Sepsis</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Severe sepsis</arm_group_label>
    <description>Patients with severe sepsis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infectious kidney stone</arm_group_label>
    <description>Patients with sepsis after PCNL for infectious kidney stone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tumor</arm_group_label>
    <description>Patients with pancreatic cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volunteer</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood sample was collected for detection of neutrophil PD-L1, monocyte HLA-DR and
      lymphocyte PD-1.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted in ICU at Changhai Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with severe sepsis

          -  patients with sepsis after PCNL for infectious kidney stone

          -  patients with pancreatic cancer

          -  healthy volunteers

        Exclusion Criteria:

          -  patients with immunodeficient diseases

          -  patients who accept glucocorticoid or immunosuppressant

          -  patients with an age older than 18 years

          -  patients providing the informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 30, 2013</lastchanged_date>
  <firstreceived_date>October 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Jia-feng Wang</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>immunosuppression</keyword>
  <keyword>PD-L1</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
